Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
Xie, Caifeng; Jin, Jiangbo; Bao, Xujie; Zhan, Wei-Hua; Han, Tian-Yu; Gan, Mingxi; Zhang, Chengfu; Wang, Jianbin.
; 7(1): 610-21, 2016 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-26575584
Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Lung Cancer: A Wily Genetic Opponent.
The biology and management of non-small cell lung cancer.
Catastrophic nuclear envelope collapse in cancer cell micronuclei.
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
Metabolic Heterogeneity in Human Lung Tumors.
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer.
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
Recognition of histone acetylation by the GAS41 YEATS domain promotes H2A.Z deposition in non-small cell lung cancer.